PSMAddition, the Integration of Lutetium-177 With the Standard of Care Therapy in Metastatic Castrate-Sensitive Prostate Cancer Patients – Scott Tagawa & Oliver Sartor

Details

In this conversation, Scott Tagawa and Oliver Sartor join Charles Ryan in a discussion on the PSMAddition clinical trial that integrates lutetium-177 with standard-of-care therapy in metastatic castration-sensitive prostate cancer (mCSPC). The trial aims to determine the efficacy and safety of lutetium-177 administered earlier in the disease course. They believe that using lutetium-177 upfront wil...